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OBJECTIVES: Literature on epidemiology of vulvar and
vaginal cancers is scarce. It has been reported that about 40%
of vulvar and 70% of vaginal cancers may be linked to human
papillomavirus (HPV). This study aimed to assess the economic
burden of vulvar and vaginal cancer and lesions in France.
METHODS: A retrospective analysis using the French hospital
database (PMSI), in which all admissions to public and private
hospitals are recorded, was performed to assess the annual
number of hospitalised patients and associated management
cost from the health care payer perspective (French Social Secu-
rity System). Admissions in 2006 for vulvar and vaginal cancers
and precancerous lesions were extracted. Radiotherapy sessions
performed in the private sector are not reported in the PMSI
and were estimated from SAE database. The mean charges for
the payer were estimated from 2007 ofﬁcial DRG (diagnosis
related group) tariffs for public and private hospitals. Outpa-
tient and daily allowance costs (paid by the health care payer)
were based on literature review. RESULTS: In 2006, the
number of hospitalised patients was estimated at 1237 and 623
for vulvar cancer and lesions and at 728 and 244 for vaginal
cancer and lesions, respectively. Annual hospital costs were esti-
mated at €5.7 million and €980,158 for vulvar cancer and
lesions and €4.0 million and €312,244 for vaginal cancer and
lesions, respectively. Adding outpatient and daily allowance
costs led to a total cost of €9.4 million and €6.7 million for,
respectively, vulvar and vaginal cancer. CONCLUSIONS: The
burden of vulvar and vaginal diseases appears to be substantial.
As the HPV6/11/16/18 vaccine is indicated for the prevention
of vaccine type-related precancerous vulvar and vaginal lesions,
these data could provide useful information for decision-
makers. Further research is needed to assess the outpatient
burden of precancerous lesions which may be mostly managed
in an outpatient setting.
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OBJECTIVES: MBD secondary to cancer can result in serious
and costly SREs. The objective of this study was to characterise
hospital burden associated with MBD and SREs following BC
and PC in Spain. METHODS: Data from IASIST’s Conjunto
Mínimo Básico Datos (CMBD) hospital activity database
(January 1, 2000–March 31, 2006) were analysed. The CMBD
database contains clinical and administrative data on hospital
admissions at 187 public and private hospitals in Spain. Patients
with an index inpatient admission of female BC or PC (ICD-9
codes 174* and 185* respectively) between January 1, 2003 and
December 31, 2003 were selected for analysis and followed until
March 31, 2006 for subsequent admissions inclusive of MBD
(ICD-9 198.5 or ICD-10 C79.5) and SREs (pathological frac-
tures, spinal cord compressions, bone surgery). Hospital length
of stay (LOS) and inpatient costs were analysed by cancer type
(BC or PC) and disease stage (index, MBD, or SRE). RESULTS:
A total of 10,090 patients were identiﬁed with BC and 7546 with
PC. The 3-year incidence rates/1000 hospital admissions, includ-
ing MBD diagnosis code and MBD&SRE diagnosis codes, were
94.7 and 20.0 for BC and 166.0 and 29.3 for PC. Readmissions
were consistent across both cancer types, with MBD + SRE
patients having the greatest number of readmissions (BC: 66%;
PC: 62%) compared to patients with cancer diagnosis only (BC:
32%; PC: 27%) and patients with cancer & MBD (BC: 58%; PC:
54%). Additionally, patients developing MBD & SREs had
greater mean total LOS (BC: 28 days; PC: 32 days) than those
with cancer only (BC: 8 days; PC: 15 days), and those with
cancer & MBD (BC: 18 days; PC: 22 days). Mean cost of
admissions increased as the disease progressed from cancer only
to MBD&SREs for BC and PC patients (€2374 to €3757 and
€3194 to €3585, respectively). CONCLUSIONS: In general,
Spanish patients with BC and PC, who develop SREs secondary
to MBD consume greater hospital resources than those with
cancer or MBD only.
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OBJECTIVES: To assess the resource utilization and direct
medical costs associated with palliative care for cancer patients in
Brazil under the private payer and the patient perspective.
METHODS: The target population consisted of adult patients
diagnosed with cancer under palliative care. A modiﬁed Delphi
panel validated and supplemented international published data,
and estimated standard treatment patterns in Brazil. The study
included only direct medical costs for managing pain, dyspnea,
depression and other complications during hospitalization, home
care or ambulatory care. The time horizon was six months, due
to the short survival of patients under palliative care. RESULTS:
During palliative care, 2% of patients needed hospitalization in
the Intensive Care Unit and 18% in a general ward; 28% were
under home care and 52% under ambulatory care. Total
weighted average direct medical costs for six months were
R$13,108 (US$8,091) per patient, of which R$8,964 (US$5,533)
were reimbursed by the private payer and R$4,144 (US$2,558)
were out-of-pocket expenses for the patient. Considering total
costs of care, the treatment of pain, dyspnea and depression
represented 19%, 14% and 10% of total costs respectively. Hos-
pitalization and home care were the major cost items, accounting
for 43% of total costs. Under the private payer perspective, these
same percentages were 4%, 16%, 0% and 63%, respectively.
Under the patients’ perspective the percentages were 51%, 11%,
32% and 0%. These differences highlight the fact that medica-
tion is only reimbursed when used during hospitalization. CON-
CLUSIONS: Palliative care is becoming a relevant ﬁeld of study
in Brazil recently. This cost of illness study estimated an average
cost of patients in six months under palliative care of R$13,108,
considering both private payer’s and patients’ out-of-pocket
costs. For the private payers the main cost item was
hospitalization/home care and for patients it was the treatment of
pain.
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OBJECTIVES: To assess the current management and resource
use, and the associated costs from the perspective of the Belgian
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health care payer in patients with ﬂuoropyrimidine, irinotecan
and oxaliplatin refractory advanced colorectal cancer.
METHODS: Data on management and resource utilization were
collected using a two round questionnaire send to a representa-
tive expert panel. Patients with 10% and those with 1–10 %
EGFR expressing tumour cells were considered separately as the
latter are theoretically excluded from reimbursement for cetux-
imab, the currently available EGFR directed agent in Belgium.
In the second round, the average, 10 and 90 percentile values of
the responses collected in the ﬁrst round were sent to each expert
who could revise his original answer, acknowledge the average
value or provide a new estimate and rank his answers on a
(un)certainty scale. Costs were obtained by multiplying the
average resource use with the speciﬁc unit cost (ofﬁcial tariffs).
Total costs included costs related to preventive measures, adverse
events, treatment evaluation and symptom control per treatment
cycle (4 or 6 w). RESULTS: Ten different treatment options were
deﬁned by the experts. If EGRF-expressing of the tumour is
10%, Irinotecan-Cetuximab is the treatment of choice in 87%
of patients and responsible for 98% of the total cost of €16,611
(95%CI:€13,271–€20,234). If EGFR-expression of the tumour is
between 1 and 10%, 48% of patients are treated by BSC alone.
BSC is responsible for 18% of the mean overall cost of €6465 per
3 months (95%CI:€4456–€8851) for a patient in this setting.
5FU-MitomycinC is the most used chemotherapy regimen in this
setting (26.04%). CONCLUSIONS: The majority of irinotecan
refractory colorectal cancer patients with a10% EGFR expres-
sion are having further active treatment with irinotecan-
cetuximab responsible for 98% of total costs. In the 1–10 %
EGFR group BSC is the most used treatment option.
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OBJECTIVES: High-risk human papilloma viruses (HPV) can
cause cervical cancer and are associated with high-grade vaginal
and vulvar lesions (especially in younger women). The objective
of the current study was to assess the economic burden of disease
for these lesions in one German hospital. METHODS: Each
patient who received at least one surgical intervention was
included in the analysis. A retrospective analysis from patient
ﬁles was conducted to determine the consumption of resources
and direct medical cost for treatment of 94 women for VIN and
VaIN 2–3 in the Department of Obstetrics and Gynecology at the
University of Düsseldorf, Germany, between 1991 and 2008
analysed retrospectively from the patients’ dossiers. The main
analysis evaluated the costs for surgical interventions and outpa-
tient visits for one year following surgery. RESULTS: A total of
113 surgical interventions (60 in-patient, 53 out-patient) were
performed. 55% of the patients had one intervention and 45%
had more than one interventions. The most frequent interven-
tions were biopsy (77%) and laser vaporisation (72%). There
were 166 out-patient visits with 137 colposcopies, 110 smears
and 60 biopsies. The average direct medical costs were 1355.49€
per patient for in-patient treatment and 208.76 € per patient for
out-patient treatment. The average direct costs for outpatient
visits in the dysplasia clinic were 59.14 € per patient. Adding
indirect costs for sick leave into the main analysis, the average
costs increased to 3451.51 € per patient. CONCLUSIONS: This
analysis provides the ﬁrst estimation of the economic burden of
high-grade vaginal and vulvar lesions in German health care
system. HPV vaccination could prevent half of the high-grade
vaginal and vulvar lesions and could signiﬁcantly reduce the
treatment costs for by these lesions.
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OBJECTIVES: To describe the management of patients with
malignant ascites and to evaluate resource consumption and
associated cost from the hospital provider’s perspective in a pilot
study. METHODS: A cross-sectional, retrospective pilot study
was performed at hospitals of maximum medical care in
Germany. Resource consumption data for e.g. number of para-
centeses, length of hospital stay, diagnostics and drugs were
obtained by patient chart abstraction. Direct medical cost was
calculated. RESULTS: In total, 27 patients with 94 hospital stays
were included in the analysis (mean age 63 years, standard
deviation [SD] 15; 56% male, mean Karnofsky index 54% SD
25). The most common underlying malignancies were gastric
carcinoma (26%), pancreatic carcinoma (15%) and colon car-
cinoma (11%). Mean number of therapeutic paracenteses per
patient was 4.5 (SD 3.8) within the time period from ascites
diagnosis to death. Mean length of hospital stay was 5.5 days
(SD 8.0). Medication mainly comprised human albumin (64%),
diuretics (20%), antibiotics (5%) and cytostatics used for intra-
peritoneal chemotherapy (3%). Mean direct cost per patient and
per hospital stay was €738 (SD1258) and €1011 (SD1584) per
hospital stay with paracentesis as reason for admission. Mean
cost per patient was €2540 (SD 2808). If cost calculation is
based on unit cost for German university hospitals, costs were
18% higher. Main cost driver was the hospital stay (60% of
costs). CONCLUSIONS: Management of malignant ascites
varies with respect to in- or outpatient paracentesis, number of
paracenteses, and concomitant medication. More data are
needed to optimize management and identiﬁcation of cost effec-
tive therapeutic options. In the ﬁeld of palliative care investiga-
tion of resource consumption and costs is challenging since the
needs and quality of life of the patients should always be taken
into consideration.
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OBJECTIVES: To evaluate the treatment cost of IFIs by compar-
ing subjects who developed a proven or probable IFI to matched
controls who did not. METHODS: Data were obtained by ret-
rospective chart review in German hospitals using a non-
randomized parallel group design in patients who have
undergone remission induction chemotherapy for newly diag-
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